Bei Akademie registrieren
Novo-Nordisk, DK0062498333

Novo-Nordisk stock at EUR 34.75 ahead of the Xetra open: pharmaceutical group

Published on 10/22/2026 at 08:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Quarterly results are listed for November 3, 2026. At Lang & Schwarz the stock trades pre-market at EUR 34.75 on October 22, 2026.

Quarterly results calendar

  • Novo Nordisk develops and sells pharmaceutical products for diabetes, obesity and rare diseases.
  • The next earnings release is listed for November 3, 2026.
  • Novo-Nordisk stock trades pre-market at EUR 34.75 at 8:32 a.m. CEST at Lang & Schwarz on October 22, 2026.
Pop-Art-Insulin-Pen im Halftone-Raster, knallbunte Primärfarben, Comic-Stil
Novo Nordisk A/S (DK0062498333): stilisierter Insulin-Pen im Pop-Art-Halftone-Raster mit knallbunten Primärfarben und Comic-Aktionslinien, Illustration mit AI erstellt.

Novo Nordisk develops and sells pharmaceutical products for diabetes, obesity and rare diseases, according to MarketScreener. Novo-Nordisk stock trades pre-market at EUR 34.75 at 8:32 a.m. CEST at Lang & Schwarz on October 22, 2026.

Ahead of the Xetra open

The price indication is EUR 34.75 at Lang & Schwarz. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Novo-Nordisk stock.

Business and the day

Novo Nordisk earns revenue from pharmaceutical products, with diabetes and obesity treatments forming its largest product family, while rare-disease medicines are another business area, according to MarketScreener. The same calendar lists the company’s third-quarter 2026 earnings release for November 3, 2026. Market context: Latest market reports.

More news and analysis on Novo-Nordisk stock

Disclaimer...
en | DK0062498333 | NOVO-NORDISK | boerse | 70390921 | bgmi